Cytek Biosciences Appoints New CFO, Maintains Revenue Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) has appointed William (Bill) McCombe as its new Chief Financial Officer. McCombe brings with him a wealth of experience, having previously served as CFO at Velo3D, HZO, and Maxar Technologies. He has significant expertise in financial management, public company reporting, operational finance, as well as mergers, acquisitions, and capital markets transactions.

McCombe's appointment comes as Cytek reaffirms its 2024 outlook, maintaining its full year 2024 revenue guidance of $203 million to $213 million. This represents a projected growth of 5% to 10% over the company's 2023 total revenue. Additionally, Cytek expects to achieve positive net income for the year ending December 31, 2024, assuming no change in currency exchange rates.

Patrik Jeanmonod, the former CFO, has been appointed as the company’s head of corporate development analytics. Dr. Wenbin Jiang, Cytek’s Chairman and CEO, expressed gratitude for Jeanmonod's instrumental role in the company's growth during a transformational period.

Cytek Biosciences, Inc. is a leading cell analysis solutions company known for its patented Full Spectrum Profiling™ (FSP™) technology. The company's product suite includes core instruments such as the Cytek Aurora™ and Northern Lights™ systems, the Cytek Aurora™ CS cell sorter, the Cytek Orion™ reagent cocktail preparation system, as well as flow cytometer and imaging products under the Amnis® and Guava® brands.

Cytek Biosciences, Inc. (NASDAQ: CTKB) is headquartered in Fremont, California, with a global presence in offices and distribution channels.

Today the company's shares have moved -1.1% to a price of $6.62. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.